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Abstract 
Introduction: Childbirth requires several changes in the function of the uterus and 
cervix. Today, various methods are used to prepare the cervix. Ripening of the cervix is 
one of the most factors in a successful delivery. This study aims to compare the effects 
of vaginal misoprostol tablet with vaginal evening primrose capsule on cervical 
ripening in nulliparous women with term pregnancy. 
Methods: This study was a randomized clinical trial of a sokor conducted on 100 
nulliparous women referred to Pasteur Hospital and Prenatal Clinic of University of 
Medical Sciences of Bam, 40 weeks to 40 weeks±6 days gestational age with Bishop 
Score less than 4. The women were selected by convenient sampling based on random 
numbers divided into two groups, evening primrose (1000 mg vaginal evening 
primrose capsules) and misoprostol (25 micrograms of vaginal misoprostol tablets). 
The data was collected by demographic and midwifery questionnaire, follow-up form, 
Bishop's checklist, fetal movement registration form, and daily record. Data were 
analyzed by SPSS20 software, independent t-test, Mann-Whitney, Chi-square, and 
Linear by Linear. In all of the tests, P < 0.05 was considered. 
Results: Bishop’s score at admission in the evening primrose group was 1.84 ± 0.88 
versus 0.78 ± 0.66 in the misoprostol group (P < 0.001). The two groups had 
significant differences in terms of dilatation and cervical consistency during admission. 
The dilatation in the evening primrose group significantly increased, and cervical 
consistency was considerably softer in the misoprostol group (P < 0.05). 
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A strong predictor for successful and uncomplicated 
delivery is a cervix with a high bishop score [1]. Cervical 
ripening is one of the central labor stages in the final 
weeks of pregnancy when the cervix begins to soften [2]. 
Termination of pregnancy in cervical Incompatibility 
cases results in increased adverse outcomes such as 
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prolonged labor, fetal distress, and increased cesarean 
section [3]. Increased fetal death, post maturity, 
metabolic acidosis, low Apgar score, meconium 
aspiration syndrome, and prolonged labor are 
complications of pregnancy that persist for more than 42 
weeks [1]. 
Different mechanical and pharmaceutical methods are 
currently used for cervical ripening [3-5]. There are 
many drugs available for the preparation of the cervix, 
which has a variety of prostaglandins. One of these is 
vaginal misoprostol tablets [6]. The systemic biological 
ability of vaginal misoprostol is more than twice that of 
its oral form [7]. Cervical susceptibility to misoprostol 
is increased during pregnancy, so that misoprostol is 
effective at 25-50 micrograms in late pregnancy and the 
early pregnancy with 400-800 micrograms [8]. 
Misoprostol is prescribed for pregnancy termination, 
especially in the third trimester, due to its high efficacy, 
excellent safety, reasonable price, ease of use, and easy 
maintenance at room temperature [9]. Side effects of 
this product have been reported in 8 - 34% [10]. In one 
study, vaginal misoprostol compared with other forms 
of it, although facilitating delivery within the first 24 
hours, also caused the highest fetal heart rate changes 
[11]. Many studies have shown that vaginal misoprostol 
is a safe drug for the cervix's preparation [12, 13].  
Nowadays, complementary medicine, especially herbal 
remedies for cervical ripening, has been increasing [14, 
15]. Some herbs have been considered and may be 
useful in cervical ripening. The evening primrose plant 
is from the Onagraceae family, scientifically named 
Oenothera biennis [16]. This plant extract contains two 
essential fatty acids (50-75% linoleic acid, 7-10% 
gamma-linoleic acid) and a small amount of oleic, 
palmitic, and stearic acid. These two essential fatty acids 
facilitate prostaglandin E2 synthesis [17, 18]. 
Some studies confirm the effects of evening primrose on 
cervical ripening [19, 20], but one study found that 
evening primrose did not affect cervical development 
[21]. The use of this plant has no restrictions on 
pregnancy [22], research has shown that its use has no 
adverse effects on fetal health [23], but can it affect 
cervical ripening? Due to the contradictory results 
regarding the effects of evening primrose on cervical 
development, the present study aimed to compare the 
impact of vaginal misoprostol tablet with vaginal 
evening primrose capsule on cervical ripening in 
primiparous women referred to Pasteur Hospital in Bam 
2018. 
METHODS 
This single-blind randomized clinical trial study was 
performed on 100 nulliparous women with term 
pregnancy. Bishop scores less than 4, referred to Pasteur 
Hospital and Prenatal Clinic affiliated with University of 
Medical Sciences Bam, Iran. It was done from April to 
November 2018. The sample size was based on the 
study's overall objective, probability of first type error of 
0.05%, test power of 0.1%, with 15% sample loss per 
group consisted of 55 patients (110 patients in total). 
Inclusion criteria included: 18-30 years of age, first and 
single pregnancy, cephalic fetus presentation, live fetus, 
gestational age 40 weeks to 40 weeks and six days based 
on the first day of last menstrual and first-trimester 
ultrasound, no uterine contractions, Bishop Score less 
than four, Intact amniotic sac, estimated fetal weight of 
2500-4000 grams, low-risk pregnancy (no known 
internal and surgical diseases and pregnancy 
complications such as previa, placental abruption, 
preeclampsia, and no known fetal problems), no vaginal 
examination during the 24 hours before the study, there 
was no sexual intercourse and herbal medicines. If they 
had any issues requiring emergency action such as fetal 
failure, maternal bleeding, etc., receiving any herbal 
medication during the study, possible drug-related 
complications, and withdrawal from participation in the 
task at each stage were excluded. Required explanations 
about the research and its aims were given to the 
women, and then informed consent was obtained from 
those who met the inclusion criteria. The women in the 
study were first available, and then they were randomly 
divided into two groups based on a random number 
table. One hundred ten envelopes were placed in a box. 
Each envelope was assigned to one of the two groups of 
misoprostol and the evening primrose based on a table 
of random numbers. The first ones took envelope 
number 1, and the next ones took the envelopes in order 
of their number and were in the assigned groups. Finally, 
100 patients, 45 were in the evening primrose group (4 
were excluded due to sexual intercourse during the 
study and six were excluded due to the lack of complete 
referral for placement of the evening primrose capsule), 
and 55 were assigned to the misoprostol group(Figure 
1). The women in both groups were unaware of the type 
of medication used. 
In the evening primrose group, the researcher referred 
to the prenatal clinic and examination room of Pasteur 
Hospital and women whose gestational age was 40 
weeks and had a Bishop examination of less than four, 
after justifying the goals and written consent were given 
1000 mg vaginal evening primrose capsule 
manufactured by Amin Drug Company for seven days. 
The women were instructed over a week until the next 
referral in case of labor pain, spotting or bleeding, 
leakage, decreased fetal movement, or any other 
problems during a telephone contact with the researcher 
to refer to the hospital's emergency clinic. In the 
misoprostol group, women referred to Pasteur Hospital 
with a gestational age of more than 40 weeks were 
selected as candidates for 25 micrograms (one eighth 
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200 micrograms) vaginal misoprostol tablets 
manufactured by Samisaz Mashhad Company. After 
taking misoprostol, the woman and her fetus were 
monitored. The researcher followed up with both 
groups until admission. The vaginal examination and 
Bishop Score were assessed in both groups by a 
researcher (experienced midwifery expert). Samples 
were also provided with the researcher's telephone 
number to contact the researcher at any time of the day 
if any problems or questions arose. At each stage of the 
onset of labor symptoms or hospitalization for any 
reason, the patient was followed up by the researcher 
from hospitalization to the end of delivery. 
Demographic and midwifery questionnaire, observation 
and examination, follow up form, daily registration form, 
and Bishop Checklist were used for data collection. Data 
were analyzed using SPSS 20 software. Kolmogorov-
Smirnov test was used to ensure normal distribution of 
data. Independent t-test and Mann-Whitney test were 
used for normal distribution of data. Chi-square tests 
were used to compare qualitative and nominal data. 
Linear by Linear association was also used for data 
analysis. A P-value less than 0.05 was considered 
significant. The Ethics Committee approved the present 
study of Shahid Beheshti University of Medical Sciences 
under IR. SBMU.PHNM.1396.851 and also registered 
in clinical trial site IRCT20180101038176N1. 
RESULTS 
This study was conducted on 100 women (55 women in 
the misoprostol group and 45 women in the primrose 
group) that showed in Figure 1, and their demographic 
details are presented in Table 1. The findings are as 
follows: The two groups were matched for maternal age 
and body mass index after analyzing data. Mean and 
standard deviation of gestational age in the evening 
primrose group at the first day of last menstruation and 
first-trimester ultrasound were respectively 40 weeks 
and 1.44 ± 1.23 days and 40 weeks and 1 ± 1.3 days, and 
in misoprostol group were 40 weeks and 2.45 ± 1.63 
days and 40 weeks and 2.38 ± 1.95 days. The two groups 
were similar in gestational age on the first day of the last 
menstrual and first-trimester ultrasound. Still, they were 
significantly different in the number of gestational days 
(on the first day of previous menstrual P = 0.001), (on 
the first-trimester ultrasound P<0.001). Gestational age 
based on the first day of last menstruation and first-
trimester ultrasound was significantly higher in the 
misoprostol group (Table 1). 
The most common cause of hospitalization in the 
evening primrose group, 18 patients (40%), was the 
pain. In the misoprostol group, 41 (74.5%) had the time 
of delivery. At the time of admission, 23 (51.1%) in the 
evening primrose group had an Intact amniotic sac, 
while in the misoprostol group, all women had an Intact 
amniotic sac. There was no significant difference 
between fetal heart rate at the beginning of the study and 
admission and fetal heart rate status during the study. 
There was a statistically significant difference between 
the two groups in terms of bleeding at admission, of 
which 5 (11.1%) in the evening primrose group and in 
the misoprostol group had 1 (1.8) patients with low 
bleeding. At admission, 40 (88.9%) of the evening 
primrose group women with uterine contraction and 54 
(98.2%) of the misoprostol group had no uterine 
contraction. At least one uterine contraction within 10 
minutes at the onset of contractions during maternity 
hospitalization was observed in 23 (52.3%) women. In 
the evening primrose group, 20 women were given one 
dose on the first day, 23 women two doses in two days, 
and two women three doses of 1000 mg capsules in 
three days vaginally on the first day. The misoprostol 
group received only one dose of 25 micrograms 
intravaginal. The type of delivery was the majority 
vaginal, 41 (91.1%) in the evening primrose group and 
49 (89.1%) in the misoprostol group. No significant 
difference was observed. There was no significant 
difference between the two groups in terms of duration 
of labor phases. 32 (72.3%) women in the evening 
primrose group and 41 (74.5%) in the misoprostol 
group used oxytocin. Hyoscine was the most commonly 
used drug during labor in the evening primrose group of 
6 patients (50%) and the misoprostol group 6 patients 
(60%). There was no statistically significant difference 
between the two groups. There was a statistically 
significant difference in the incidence of side effects 
between the two groups in terms of nausea and 
vomiting, with nausea and vomiting higher in the 
misoprostol group (12 (26.7%) in the evening primrose 
group and 36(65.5%) in the misoprostol group 
(P<0.001). There was no significant difference between 
the two groups in terms of meconium-stained amniotic 
fluid, fetal heart rate changes, diarrhea, and bleeding. 
None of the women studied had a fever and a 
contraction more significant than 6 in 10 minutes. 
There was a significant difference between the two 
groups regarding Bishop Score at admission, and this 
score was significantly higher in the evening primrose 
group (p <0.001) (Table 2). There was a significant 
difference between the two groups at the entrance in 
terms of cervical dilatation and consistency. Dilatation 
was significantly higher in women of the evening 
primrose group (P < 0.001), but the cervical texture was 
softer in the misoprostol group (P < 0.001) (Table 3).  
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Figure 1. The Consort Flowchart 
 
Table 1. Comparing of Demographic Data of the Women in the Two Groups of Evening Primrose and Misoprostol. 
Variable Evening primrose group N=45 Misoprostol Group N=55 P-Value 
Mother's age 22.29 ± 4.04a 22.49 ± 3.37 0.786* 
Mother weight 61.84 ± 9.96 60.82 ± 7.75 0.757** 
BMI 23.1 ± 2.89 22.87 ± 2.38 0.658* 
First day of last menstruation 40w&1.44 ± 1.23 40w&2.45 ± 1.63 0.001** 
First trimester ultrasound 40w&1± 1.3 40w&2.38 ± 1.95 <0.001** 
Maternal education   0.621*** 
Elementary 6(13.3)b 5(9.1)  
Secondary school 7(15.6) 10(18.2)  
High school 21(46.7) 21(38.2)  
Academic 11(24.4) 19(34.5)  
Employment status of the mother   0.088*** 
Housewife 42(93.3) 45(81.8)  
Employee 3(6.7) 10(18.2)  
Attend delivery preparation classes   0.296*** 
Yes 9(20) 15(27.28)  
No 36(80) 40(72.72)  
Prenatal exercise   0.805*** 
Yes 5(11.1) 7(12.7)  
No 40(88.9) 48(87.3)  
Number of prenatal care sessions   0.293** 
1-3 sessions 1(2.2) 1(1.8)  
3-5 sessions 4(8.9) 7(12.7)  
More than 5 sessions 40(88.9) 47(85.5)  
* Independent t-test, ** Mann-Whitney test, *** Chi-square test 
Data in the table are presented as Mean ± SD or No. (%) 
 
Table 2. Comparing of Bishop's Score at Different Times in the Women in the Two Groups of Evening Primrose and Misoprostol. 
Bishop's Score at Different Times Evening Primrose Group, N = 45 Misoprostol, Group, N = 55 P-Value 
Before starting the study 0.95 ± 0.75 0.78 ± 0.66 0.259* 
At admission 1.84 ± 0.88 0.78 ± 0.66 < 0.001* 
At the beginning of the active phase 5.38 ± 0.93 5.19 ± 1.114 0.272* 
2 hours after active phase  9.24 ± 1.88 9.33 ± 1.9 0.796* 
4 hours after active phase 11.65 ± 0.9 11.81 ± 0.654 0.784* 
* Mann-Whitney test 
Data in the table are presented as Mean ± SD 
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Table 3. Comparing of Components of Bishop’s Scoring System at the Time of Admission of the Women in the Two Groups of Evening Primrose and 
Misoprostol. 
Bishop System Components Evening Primrose Group, N=45 Misoprostol Group, N=55 P Value 
Cervical dilatation   <0.001* 
Closed 2(4.5) 29(52.7)  
1-2 41(91.1) 26(47.3)  
3-4 2 (4.4) 0  
Cervical consistency   <0.001** 
Firm 43(95.6) 35(63.6)  
Medium 2(4.4) 20(36.4)  
Soft 0 0  
Cervical Status   0.182* 
Posterior 33(73.3) 34(61.8)  
Middle 12(26.7) 20(36.4)  
Anterior 0 1(1.8)  
Cervical effacement    
0-30 45(100) 55(100)  
40-50 0 0  
60-70 0 0  
80=< 0 0  
Station of the fetal head    
-3 45(100) 55(100)  
-2 0 0  
-1 0 0  
+1,+2 0 0  
* Linear by Linear Association, ** Chi-square test 
Data in the table are presented as No. (%) 
 
DISCUSSION 
This single-blind randomized clinical trial study was 
performed on 100 nulliparous women with term 
pregnancy. Bishop scores less than 4, referred to Pasteur 
Hospital and Prenatal Clinic affiliated with University of 
Medical Sciences Bam, Iran. The study aims to compare 
the effects of vaginal misoprostol tablet with vaginal 
evening primrose capsule on cervical ripening in 
nulliparous women with term pregnancy. The finding of 
the current research, Bishop’s score at admission in the 
evening primrose group, is higher than the misoprostol 
group. The dilatation in the evening primrose group 
significantly increased, and cervical consistency was 
considerably softer in the misoprostol group. Cervix 
ripening is one of the success factors in labor and 
delivery. According to the present study's findings, 
Bishop's score at admission, despite not having a 
statistically significant difference at the beginning of the 
research in the two groups, was significantly higher in 
women of the evening primrose group. Ty-Torredes et 
al. (2006) [23] and Bahmani et al. (2019) [20] have 
shown in their studies that the evening primrose capsule 
increases Bishop's score effectively and significantly. It is 
noteworthy that in the study of Bahmani et al. (2019), 
in the intervention group, vaginal evening primrose 
capsule combined with sublingual misoprostol tablets 
could be used up to two doses, which may be due to the 
positive effect of Bishop Score sublingual misoprostol 
[20], In the present study, however, the impact of 
vaginal evening primrose capsule alone in the evening 
primrose group on cervix ripening was assessed. Vahdat 
et al. (2015) also showed that evening primrose capsules 
could also affect cervical ripening in non-pregnant 
women [19]. But Jahdi et al. (2016) [21] and Kalati et 
al. (2018) [24] showed that oral evening primrose 
capsules did not affect Bishop Score increase. Perhaps 
the reason for the differences in the results of studies is 
using different evening primrose capsules doses and 
how to use it. In this study, a vaginal evening primrose 
capsule was used once daily, but Jahdi et al. (2016) [21] 
and Kalati et al. (2018) [24] used an oral evening 
primrose capsule twice daily. Some researchers have 
reported that oral evening primrose capsules during 
pregnancy and prolonged lactation labor increased 
prolonged rupture of membranes, the arrest of descent, 
oxytocin use, and vacuum delivery [25]. The Natural 
Medicines Comprehensive Database states that oral 
evening primrose capsules may be avoided during 
pregnancy due to possible pregnancy-related 
complications [26]. These side effects may be due to the 
use of extended and long-term doses of evening 
primrose capsules. Batukan et al. (2008), in their study, 
identified one of the possible mechanisms of effective 
absorption of vaginal misoprostol, its direct transfer 
from the vagina to the uterus [27]. Possibly the vaginal 
evening primrose capsule with the same mechanism 
localized absorption. One of the results of this study is 
the effect of evening primrose capsules on cervical 
dilatation. In their research, Vahdat et al. (2015) showed 
that evening primrose is useful on cervical dilatation 
[19]. In the study by Aquino et al. (2011), the evening 
primrose capsule effect on cervical dilatation was 
evident, but the researchers used 2000 mg evening 
primrose capsule [28]. Linoleic acid from the evening 
primrose converts to arachidonic acid during a number 
of enzymatic processes. Finally, arachidonic acid by 
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cyclooxygenase facilitates the synthesis of prostaglandin 
E2 from the evening primrose capsule [17, 29]. 
Prostaglandin E2 physiologically increases cervical 
readiness by increasing water under the cervical mucosa 
and altering collagen bands [30]. It is worth noting that 
cervix is composed mainly of fibroblast cells and 
connective tissue composed of collagen and glucose 
aminoglycans. Cervix preparation is an active 
biochemical process in which a series of extensive 
collagenase reactions occur. In the collagenase process, 
type 1 and 8 metalloproteinase are essential. Type1 
metalloproteinase are produced by fibroblast cells and 
type 8 by predominantly neutrophils (leukocytes). 
Studies have shown that prostaglandin E2 has a direct 
effect on stimulating the activity of type 1 
metalloproteinase [31, 32] and that prostaglandins can 
increase the level of type 8 metalloproteinase by 
adsorption of neutrophils into the cervix [33]. This 
leads to increased collagenase activity and further 
softening of the cervix. Therefore, it can be considered 
as a positive effect of evening primrose capsule on 
cervical readiness by increasing prostaglandin E2. 
Another result of this study was the difference in cervical 
consistency. Misoprostol caused softness of the cervix. 
Oppegaard et al. (2010), Confess misoprostol can be 
used to soften the cervix [34]. The softening effect is due 
to its direct impact on the cervical tissue. Although its 
mechanism is unclear but, reducing the amount of 
cervical collagen and increasing its solubility and activity 
of collagen degrading enzymes may be one of the 
possible tools of this product [12]. However, its use 
(oral-vaginal) also be of interest. Perhaps the reason for 
the firm of the cervical consistency in women of the 
evening primrose group is the short duration of capsule 
use. Most of these women had been admitted to the 
hospital on the first day after capsule application. 
Other findings of the study showed that the incidence of 
adverse events such as nausea and vomiting was 
significantly higher in women in the misoprostol group 
than in the evening primrose group. Still, Jahromi et al. 
(2016), in their study, showed no significant difference 
in adverse events except meconium-stained amniotic 
fluid and change in fetal heart rate [35]. The most 
common side effect of misoprostol is gastrointestinal 
side effects that are dose-dependent [8, 11]. In the study 
of Bahmani et al. (2019), no side effects were found in 
women using vaginal evening primrose [20].  
In this study, the rate of bleeding at admission was 
higher in the evening primrose group due to the higher 
dilatation rate. Bloody show can be attributed to cervical 
dilatation. Also, some women in the evening primrose 
group had amniotic rupture sacs at the time of 
hospitalization. Perhaps this was due to the effect of the 
evening primrose on the cervix. As a result of uterine c 
ontractions, the amniotic sac's hydrostatic effect leads to 
the dilatation of the cervix [1]. Therefore, uterine 
contraction intensity can be a possible cause of amniotic 
sac rupture in this group.  
Considering the effect of all Bishop Score components 
on the chance of vaginal delivery, although a related 
study can be stated, cervical dilatation is the most critical 
component of Bishop Score for cervical ripening in the 
successful prediction of labor induction [36]. 
CONCLUSIONS 
This study showed that a vaginal evening primrose 
capsule could effective on cervical ripening and 
dilatation. However, various factors affect the bishop 
score. Researchers recommend considering this method 
as an affordable, inexpensive, and uncomplicated way to 
improve labor and delivery compared to other methods. 
Further studies and their effect on delivery outcomes are 
suggested to obtain more definitive results regarding the 
evening primrose capsule's efficacy on cervical ripening. 
The most vital point of the study is introducing a herbal 
material that facilitated childbirth with the least side 
effects. One of the limitations of this study is that it is a 
single-blind survey, repeated vaginal examinations of 
midwives in labor, and chemical drugs in work.  
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